中国医药科学杂志欢迎您.   今天是:        
严文琼1,廖湘交1,陈立勇1,王海霞1,范长河2.舒肝解郁胶囊联合喹硫平治疗首发精神分裂症的疗效及对氧化应激水平的影响[J].中国医药科学,2019,(16):73-77        基金项目:
舒肝解郁胶囊联合喹硫平治疗首发精神分裂症的疗效及对氧化应激水平的影响
Effect of Shugan Jieyu capsule combined with quetiapine on clinical efficacy and oxidative stress level of first-episode schizophrenia
  
DOI:
中文关键词:  舒肝解郁胶囊;喹硫平;首发精神分裂症;氧化应激
英文关键词:Shugan Jieyu Capsule;Quetiapine;First-episode Schizophrenia;Oxidative Stress
作者单位
严文琼1,廖湘交1,陈立勇1,王海霞1,范长河2 1. 广州市民政局精神病院医务部,广东广州 510430;2. 广东省人民医院 广东省精神卫生中心,广东广州 510120 
摘要点击次数: 4
全文下载次数: 9
中文摘要:
      [摘要] 目的 观察舒肝解郁胶囊联合喹硫平治疗首发精神分裂症的疗效及对氧化应激水平的影响。 方法 选取 2017 年 5 月~ 2018 年 10 月我院收治的确诊为首发精神分裂症患者 80 例为研究对象,按随机原则分为两组。对照组 40 例患者给予口服喹硫平治疗,观察组 40 例患者给予口服舒肝解郁胶囊联合喹硫平治疗,观察两组患者 PANSS 评分、临床疗效、氧化应激性水平及安全性等方面的差异。 结果 观察组治疗后第21 天及第 42 天阳性症状、阴性症状、精神病理、PANSS 总分均明显低于对照组(P < 0.05);观察组痊愈、显著进步患者明显多于对照组,观察组总有效率为 92.5% 与对照组总有效率 87.5% 比较,差异无统计学意义(P > 0.05);治疗后,两组患者血清中 T-SOD、GSH-Px 含量均明显升高(P < 0.05),而 CAT 及 MDA含量显著降低(P < 0.05),而观察组患者各指标增高或降低程度较对照组明显(P < 0.05);观察期间两组不良反应症状发生率比较,差异均无统计学意义(P > 0.05)。 结论 舒肝解郁胶囊联合喹硫平可有效改善首发精神分裂症患者临床症状,安全性高,有助于患者氧化应激能力的提升。
英文摘要:
      [Abstract] Objective To observe the effect of Shugan Jieyu Capsule combined with quetiapine on clinical efficacy and oxidative stress level of first-episode schizophrenia. Methods 80 patients diagnosed with first-episode schizophrenia admitted to our hospital from May 2017 to October 2018 were enrolled in the study.They were divided into two groups according to the random principle.The control group(40 patients) was treated with quetiapine orally,and the observation group (40 patients) was given Shugan Jieyu capsule combined with quetiapine orally.The differences of PANSS score,clinical efficacy,oxidative stress level and safety between two groups were observed. Results The positive symptoms,negative symptoms,psychopathology and PANSS scores in observation group were significantly lower than control group on the 21st and 42nd after treatment (P < 0.05).Although the total effective rate of observation group(92.5%) was no significantly higher than control group(87.5%)(P > 0.05),the number of patients recovered and improved significantly in observation group was significantly higher than control group (P < 0.05).After treatment,the serum T-SOD and GSH-Px levels in both groups were significantly increased (P < 0.05),while the levels of CAT and MDA were significantly decreased (P < 0.05),while the indexes in observation group were significantly higher or lower than those in control group (P < 0.05).There was no significant difference in the incidence of adverse reactions between two groups during the observation period (P > 0.05). Conclusion Shugan Jieyu Capsule combined with quetiapine can effectively improve the clinical symptoms of first-episode schizophrenia,especially the negative symptoms.It has high safety and is helpful to enhance the oxidative stress ability of patients.
查看全文  查看/发表评论  下载PDF阅读器
关闭
关键词: 中国医药科学 中国医学 中国医学科学 中华医学 医学杂志 临床医学杂志 医学期刊 中国预防医学 中华预防医学 预防医学杂志 中国药学 药学杂志
药理杂志 中国中医 中医杂志 中华中医药 中医药杂志 中国医疗 医疗器械杂志 中国中西医结合 中国医药 医药杂志 医药期刊 医药论文 医学论文 科研论文 职称论文
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=FF4EC6B96077DFE75382991EEED1840C8438AA96E8E0E6687DCBE18EF21FED191DCCA93BBB33078B1DEEC704CD662510363C34CA9A62BE36BF80FFE98DBCEBE74D09525683CD6EAFD7B7BB24B4A19AC1B5E73B9DF9F73E5C4D8CF6F0ED51056A6BAEB22FF4CC4988B3F179CF0A7E77AD22CE7CC192DA46326D8F87E6EC62C0209A5899CC4C0689EC&pcid=&cid=&jid=&yid=B6351343F4791CA3&aid=&vid=&iid=7801E6FC5AE9020C&sid=B9704B40A4225A24&eid=E44E40A2398D4F2A&fileno=20191150&flag=1&is_more=0">